Abstract
Meeting abstracts T-VEC is an HSV-1-derived oncolytic immunotherapy designed to selectively replicate within tumors, produce GM-CSF and enhance systemic antitumor immune responses. In OPTiM ([NCT00769704][1]), a randomized Phase III trial of intralesional T-VEC vs subcutaneous GM-CSF for unresected
Highlights
Talimogene Laherparepvec (T-VEC) is an HSV-1-derived oncolytic immunotherapy designed to selectively replicate within tumors, produce GM-CSF and enhance systemic antitumor immune responses
Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
For patients who had a DR vs those who did not, HRs for improved OS were 0.08, 0.05 and 0.13 at 9, 12 and 18 months, respectively, indicating that achieving a DR is associated with improved OS
Summary
Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial. Howard L Kaufman1*, Robert HI Andtbacka, Frances A Collichio, Michael Wolf, Ai Li4, Mark Shilkrut, Igor Puzanov, Merrick Ross. From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. From Society for Immunotherapy of Cancer 29th Annual Meeting National Harbor, MD, USA. 6-9 November 2014
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
